| 000 |
|
00000cam u2200205 a 4500 |
| 001 |
|
000045984704 |
| 005 |
|
20190528164429 |
| 006 |
|
m d |
| 007 |
|
cr |
| 008 |
|
190527s2017 dcua ob 000 0 eng |
| 020 |
|
▼a 9780309455091 (electronic bk.)
|
| 020 |
|
▼a 030945509X (electronic bk.)
|
| 020 |
|
▼a 9780309455084
|
| 020 |
|
▼a 0309455081
|
| 020 |
|
▼a 030945509X
|
| 035 |
|
▼a 1546468
▼b (N$T)
|
| 035 |
|
▼a (OCoLC)1002295899
▼z (OCoLC)992148188
▼z (OCoLC)992318214
▼z (OCoLC)992570855
|
| 040 |
|
▼a NLM
▼b eng
▼e rda
▼c NLM
▼d SCB
▼d EBLCP
▼d YDX
▼d MMU
▼d MERUC
▼d OCLCF
▼d MERER
▼d N$T
▼d 211009
|
| 043 |
|
▼a n-us---
|
| 050 |
0
0
|
▼a QH499
|
| 082 |
0
0
|
▼a 571.8/89
▼2 23
|
| 084 |
|
▼a 571.889
▼2 DDCK
|
| 090 |
|
▼a 571.889
|
| 245 |
0
0
|
▼a Exploring the state of the science in the field of regenerative medicine
▼h [electronic resource] :
▼b challenges of and opportunities for cellular therapies : proceedings of a workshop /
▼c Ariel Markowitz-Shulman ... [et al.], rapporteurs ; Forum on Regenerative Medicine, Board on Health Sciences Policy, Health and Medicine Division, the National Academies of Sciences, Engineering, Medicine.
|
| 260 |
|
▼a Washington, DC :
▼b National Academies Press,
▼c 2017.
|
| 300 |
|
▼a 1 online resource :
▼b ill.
|
| 500 |
|
▼a Title from e-Book title page.
|
| 504 |
|
▼a Includes bibliographical references.
|
| 505 |
0
|
▼a Introduction -- Skin and musculoskeletal tissues -- Hematologic and immunologic applications -- Neurological and ophthalmological tissues -- Cardiovascular and lung tissues -- Renal tissue -- Looking toward the future: concluding thoughts -- References -- Appendix A: Workshop agenda -- Appendix B: Speaker biographical sketches -- Appendix C: Statement of task -- Appendix D: Registered attendees.
|
| 520 |
3
|
▼a Regenerative medicine holds the potential to create living, functional cells and tissues that can be used to repair or replace those that have suffered potentially irreparable damage due to disease, age, traumatic injury, or genetic and congenital defects. The field of regenerative medicine is broad and includes research and development components of gene and cell therapies, tissue engineering, and non-biologic constructs. Although regenerative medicine has the potential to improve health and deliver economic benefits, this relatively new field faces challenges to developing policies and procedures to support the development of novel therapies are both safe and effective. In October 2016, the National Academies of Sciences, Engineering, and Medicine hosted a public workshop with the goal of developing a broad understanding of the opportunities and challenges associated with regenerative medicine cellular therapies and related technologies. Participants explored the state of the science of cell-based regenerative therapies within the larger context of patient care and policy. This publication summarizes the presentations and discussions from the workshop.
|
| 530 |
|
▼a Issued also as a book.
|
| 536 |
|
▼a This project was supported by contracts between the National Academy of Sciences and Akron Biotech (unnumbered contract); Alliance for Regenerative Medicine (unnumbered contract); ALS Association (unnumbered contract); American Association of Gene and Cell Therapy (unnumbered contract); Burroughs Wellcome Fund (Grant #1015949); California Institute for Regenerative Medicine (unnumbered contract); Centre for Commercialization of Regenerative Medicine (unnumbered contract); Christopher & Dana Reeve Foundation (unnumbered contract); Department of Veterans Affairs (Contract No. VA268-16-C-0051); Food and Drug Administration (Grant #1R13FD005355-01); Foundation Fighting Blindness (unnumbered contract); GE Healthcare (unnumbered contract); GlaxoSmithKline (Grant ID: 015948); International Society for Stem Cell Research (unnumbered contract); Johnson & Johnson (unnumbered contract); Juno Therapeutics (unnumbered contract); The Michael J. Fox Foundation for Parkinson's Research (unnumbered contract); National Institute of Standards and Technology (unnumbered contract); National Institutes of Health (Contract No. HHSN263201200074I, Order No. HHSN23600075: National Heart, Lung, and Blood Institute; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Biomedical Imaging and Bioengineering; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Neurological Disorders and Stroke); The New York Stem Cell Foundation (unnumbered contract); Parkinson's Disease Foundation (unnumbered contract); Takeda Development Centers America (Contract #65317); and United Therapeutics Corporation (unnumbered contract). Any opinions, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project.
|
| 538 |
|
▼a Mode of access: World Wide Web.
|
| 650 |
1
2
|
▼a Cell- and Tissue-Based Therapy
▼x methods.
▼0 https://id.nlm.nih.gov/mesh/D064987Q000379.
|
| 650 |
1
2
|
▼a Regenerative Medicine
▼x methods.
▼0 https://id.nlm.nih.gov/mesh/D044968Q000379.
|
| 650 |
2
2
|
▼a Health Policy.
▼0 https://id.nlm.nih.gov/mesh/D006291.
|
| 650 |
2
2
|
▼a Patient Care.
▼0 https://id.nlm.nih.gov/mesh/D005791.
|
| 650 |
0
|
▼a Regenerative medicine
▼v Congresses.
|
| 700 |
1
|
▼a Markowitz-Shulman, Ariel.
|
| 710 |
2
|
▼a National Academies of Sciences, Engineering, and Medicine (U.S.).
▼b Forum on Regenerative Medicine.
|
| 711 |
2
|
▼a State of the Science in the Field of Regenerative Medicine: Challenges of and Opportunities for Cellular Therapies (Workshop)
▼d (2016 :
▼c Washington, D.C.).
|
| 856 |
4
0
|
▼3 EBSCOhost
▼u https://oca.korea.ac.kr/link.n2s?url=http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=1546468
|
| 945 |
|
▼a KLPA
|
| 991 |
|
▼a E-Book(소장)
|
